Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
2.940
-0.460 (-13.53%)
At close: Aug 14, 2026, 4:00 PM EDT
2.990
+0.050 (1.70%)
After-hours: Aug 14, 2026, 7:55 PM EDT
Aptevo Therapeutics Employees
Aptevo Therapeutics had 33 employees as of December 31, 2025. The number of employees decreased by 4 or -10.81% compared to the previous year.
Employees
33
Change (1Y)
-4
Growth (1Y)
-10.81%
Revenue / Employee
n/a
Profits / Employee
-$798,576
Market Cap
3.66M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 33 | -4 | -10.81% |
| Dec 31, 2024 | 37 | -3 | -7.50% |
| Dec 31, 2023 | 40 | -5 | -11.11% |
| Dec 31, 2022 | 45 | -9 | -16.67% |
| Dec 31, 2021 | 54 | -4 | -6.90% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| PMGC Holdings | 34 |
| Curis | 24 |
| TransCode Therapeutics | 12 |
| Ensysce Biosciences | 10 |
| Revelation Biosciences | 9 |
| Galmed Pharmaceuticals | 6 |
| Mustang Bio | 4 |
| Creative Medical Technology Holdings | 4 |
APVO News
- 21 hours ago - Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results - Accesswire
- 1 day ago - Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds - Accesswire
- 2 days ago - Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds - Accesswire
- 18 days ago - Aptevo files patent application for Nectin-4 x PD-L1 dual-targeting backbone - TheFly
- 18 days ago - Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone - Accesswire
- 6 weeks ago - Aptevo Therapeutics awarded $1.5M research grant from Andy Hill CARE Fund - TheFly
- 6 weeks ago - Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors - Accesswire
- 2 months ago - Aptevo Therapeutics appoints Janatpour as SVP, CSO - TheFly